Companies news
Horus Pharma: Bringing French Ophthalmic Expertise to Asia
Founded in 2003, Horus Pharma is a 100% independent French pharmaceutical laboratory specialized in ophthalmology.
Headquartered in Nice and recognized as a key player in Europe with over two decades of double-digit growth, the company has built its reputation on innovation (10% of the annual revenue is allocated to R&D each year), independence, and a strong commitment to addressing the needs of both patients and eye care professionals.
Horus Pharma develops, patents, and markets a comprehensive range of innovative eye care solutions—including medicines, medical devices, human tissues, dietary supplements, and cosmetics—designed to treat all types of ocular conditions, from common to rare. A pioneer in preservative-free formulations, the company is driven by its mission to improve patients’ quality of life through effective products. As it sets its sights beyond Europe, Horus Pharma is taking a significant step into Asia, beginning with Vietnam and continuing with participation in the Business France delegation to Southeast Asia, especially in Singapore, to explore new partnerships and growth opportunities.
International development: a strategic pillar of growth
Over the past decade, Horus Pharma has pursued an ambitious international expansion strategy. In addition to its presence in France, the company is active in around 30 countries, through subsidiaries in Spain, Belgium, the Netherlands, Switzerland, and the Nordic countries, a joint venture in Romania, and various distribution agreements (EMEA region). Over the years, the company has built a solid network of affiliates and partners. In 2024, international sales accounted for 15% of its revenue.
"Alongside innovation, international development is one of the main pillars of our growth," explains Nicolas Claret, International Director of Horus Pharma. " Adapting our solutions to the specific needs of each market should allow us to build long-term local partnerships."
This approach has guided the company's gradual expansion abroad. While consolidating its position in Europe, Horus Pharma is also turning to Asia, where the demand for eye care is growing rapidly.
Vietnam: the first step in South-East Asia
The company’s entry into Vietnam in 2025 marks an important milestone in its international journey. In partnership with a local distributor TEDIS Horus Pharma introduced a selection of its best-selling ophthalmic products to the Vietnamese market, including preservative-free artificial tears and dietary supplements for eye health.
Vietnam was chosen for its dynamic health sector, growing middle class, and commitment to modernizing healthcare infrastructures. With a population of 100 million and an aging demographic, the country is facing a rise in ocular conditions such as dry eye, glaucoma, and age-related macular degeneration.
“Our products meet a real medical need in Vietnam, particularly in terms of preventive eye care and patient comfort,” says Nicolas Claret International Director. “We’ve been very encouraged by the positive reception from healthcare professionals and patients alike thanks to the deep expertise of TEDIS.”
South-East Asia: A region of strategic interest
Encouraged by its initial step in Vietnam, Horus Pharma is actively exploring new opportunities across Southeast Asia. The company’s participation in the Business France delegation to Singapore and the region is part of this strategic vision.
“Asia represents a major growth axis for Horus Pharma,” continues Nicolas Claret. “We are looking to develop new partnerships, meet distributors, and better understand the regulatory and market specificities of the region.”
Horus Pharma sees great potential in Asia’s fast-growing ophthalmology markets, where the demand for eye care is increasing. An ageing population and environmental factors (overexposure to screens, pollution, etc.) are contributing to an increase in eye disorders, particularly chronic diseases, creating a growing need for innovative care.
The company aims to rely on local partners who understand the specificities of the market and the needs of healthcare professionals in order to offer solutions tailored to patients.
A Responsible and Sustainable Vision
Beyond its products, Horus Pharma is recognized for its ethical and environmental commitments. The company is deeply engaged in a strategy that combines economic performance with sustainable development — from the eco-design of its products to supporting healthcare professionals in reducing the environmental impact of their practices.
Building bridges with Singapore and Southeast Asia
Singapore is a strategic gateway to Asia for Horus Pharma. The city-state’s cosmopolitan healthcare ecosystem, business-friendly environment, and regional influence make it an ideal location to forge new partnerships.
The company looks forward to connecting with local healthcare players, distributors, and innovation hubs during its visit, and is open to opportunities for collaboration.
“We are proud to represent French excellence in ophthalmology and look forward to contributing to better eye health across Asia,” concludes Nicolas Claret.
SOURCE: HORUS PHARMA
